The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes

Translational Research

Volumn 161, Issue 3, 2013, Pages 145-155

  Beck, George R ^a   Khazai, Natasha B ^a   Bouloux, Gary F ^a   Camalier, Corinne E ^a   Lin, Yiming ^a   Garneys, Laura M ^a   Siqueira, Joselita ^a   Peng, Limin ^b   Pasquel, Francisco ^a   Umpierrez, Denise ^a   Smiley, Dawn ^a   Umpierrez, Guillermo E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTE PROTEIN 2; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; GLUCOSE; METFORMIN; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ADULT; ARTICLE; BONE MARROW STROMAL CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL LINEAGE; CLINICAL ARTICLE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MINERALIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOBLAST; PRIORITY JOURNAL; STROMA CELL;

EID: 84873936996     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.08.006     Document Type: Article

References (53)

1. H. Yki-Jarvinen The PROactive study: some answers, many questions Lancet 366 2005 1241 1242
2. C. Meier, M.E. Kraenzlin, M. Bodmer, S.S. Jick, H. Jick, and C.R. Meier Use of thiazolidinediones and fracture risk Arch Intern Med 168 2008 820 825
3. J.J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone N Engl J Med 331 1994 1188 1193
4. M. Bajaj, S. Suraamornkul, S. Kashyap, K. Cusi, L. Mandarino, and R.A. DeFronzo Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes J Clin Endocrinol Metab 89 2004 4649 4655
5. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J Biol Chem 270 1995 12953 12956
6. T.M. Willson, J.E. Cobb, D.J. Cowan, R.W. Wiethe, I.D. Correa, and S.R. Prakash The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones J Med Chem 39 1996 665 668
7. T.M. Willson, J.M. Lehmann, and S.A. Kliewer Discovery of ligands for the nuclear peroxisome proliferator-activated receptors Ann N Y Acad Sci 804 1996 276 283
8. H. Yki-Jarvinen Thiazolidinediones N Engl J Med 351 2004 1106 1118
9. T.A. Buchanan, A.H. Xiang, R.K. Peters, S.L. Kjos, A. Marroquin, and J. Goico Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women Diabetes 51 2002 2796 2803
10. H.C. Gerstein, S. Yusuf, J. Bosch, J. Pogue, P. Sheridan, and N. Dinccag Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 2006 1096 1105
11. R.A. DeFronzo, D. Tripathy, D.C. Schwenke, M. Banerji, G.A. Bray, and T.A. Buchanan Pioglitazone for diabetes prevention in impaired glucose tolerance N Engl J Med 364 2011 1104 1115
12. S. Yaturu, B. Bryant, and S.K. Jain Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men Diabetes Care 30 2007 1574 1576
13. D.H. Solomon, S.M. Cadarette, N.K. Choudhry, C. Canning, R. Levin, and T. Sturmer A cohort study of thiazolidinediones and fractures in older adults with diabetes J Clin Endocrinol Metab 94 2009 2792 2798
14. T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, and P.P. Vescovi Vertebral fractures in males with type 2 diabetes treated with rosiglitazone Bone 45 2009 784 788
15. A.V. Schwartz, D.E. Sellmeyer, E. Vittinghoff, L. Palermo, B. Lecka-Czernik, and K.R. Feingold Thiazolidinedione use and bone loss in older diabetic adults J Clin Endocrinol Metab 91 2006 3349 3354
16. A. Grey, M. Bolland, G. Gamble, D. Wattie, A. Horne, and J. Davidson The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 92 2007 1305 1310
17. A. Grey Thiazolidinedione-induced skeletal fragility-mechanisms and implications Diabetes Obes Metab 11 2009 275 284
18. A.K. McDonough, R.S. Rosenthal, X. Cao, and K.G. Saag The effect of thiazolidinediones on BMD and osteoporosis Nat Clin Pract Endocrinol Metab 4 2008 507 513
19. A.V. Schwartz Diabetes, TZDs, and bone: a review of the clinical evidence PPAR Res 2006 2006 24502
20. A.V. Schwartz TZDs and bone: a review of the recent clinical evidence PPAR Res 2008 2008 297893
21. J.N. Beresford, J.H. Bennett, C. Devlin, P.S. Leboy, and M.E. Owen Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures J Cell Sci 102 Pt 2 1992 341 351
22. G. Karsenty Transcriptional control of skeletogenesis Annu Rev Genomics Hum Genet 9 2008 183 196
23. E.D. Rosen, and B.M. Spiegelman Molecular regulation of adipogenesis Annu Rev Cell Dev Biol 16 2000 145 171
24. J.M. Gimble, C.E. Robinson, X. Wu, K.A. Kelly, B.R. Rodriguez, and S.A. Kliewer Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells Mol Pharmacol 50 1996 1087 1094
25. S.O. Rzonca, L.J. Suva, D. Gaddy, D.C. Montague, and B. Lecka-Czernik Bone is a target for the antidiabetic compound rosiglitazone Endocrinology 145 2004 401 406
26. A.A. Ali, R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, and R.L. Jilka Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 146 2005 1226 1235
27. V. Sottile, K. Seuwen, and M. Kneissel Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone) Calcif Tissue Int 75 2004 329 337
28. M.A. Soroceanu, D. Miao, X.Y. Bai, H. Su, D. Goltzman, and A.C. Karaplis Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J Endocrinol 183 2004 203 216
29. G.R. Beck Jr., E.C. Sullivan, E. Moran, and B. Zerler Relationship between alkaline phosphatase levels, osteopontin expression, and mineralization in differentiating MC3T3-E1 osteoblasts J Cell Biochem 68 1998 269 280
30. M. Owen, and A.J. Friedenstein Stromal stem cells: marrow-derived osteogenic precursors Ciba Found Symp 136 1988 42 60
31. J.N. Beresford Osteogenic stem cells and the stromal system of bone and marrow Clin Orthop Relat Res 1989 270 280
32. P.H. Krebsbach, S.A. Kuznetsov, P. Bianco, and P.G. Robey Bone marrow stromal cells: characterization and clinical application Crit Rev Oral Biol Med 10 1999 165 181
33. C. Bruedigam, M. Eijken, and M. Koedam A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone Stem cells 28 2010 916 927
34. T.E. Johnson, R. Vogel, S.J. Rutledge, G. Rodan, and A. Schmidt Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells Endocrinology 140 1999 3245 3254
35. S. Hallakou, L. Doare, F. Foufelle, M. Kergoat, M. Guerre-Millo, and M.F. Berthault Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat Diabetes 46 1997 1393 1399
36. Y. Mori, Y. Murakawa, K. Okada, H. Horikoshi, J. Yokoyama, and N. Tajima Effect of troglitazone on body fat distribution in type 2 diabetic patients Diabetes Care 22 1999 908 912
37. I.E. Kelly, T.S. Han, K. Walsh, and M.E. Lean Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes Diabetes Care 22 1999 288 293
38. Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, and K. Cusi Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J Clin Endocrinol Metab 87 2002 2784 2791
39. R. Siersbaek, R. Nielsen, and S. Mandrup Transcriptional networks and chromatin remodeling controlling adipogenesis Trends Endocrinol Metab 23 2012 56 64
40. J.T. Crossno Jr., S.M. Majka, T. Grazia, R.G. Gill, and D.J. Klemm Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells J Clin Invest 116 2006 3220 3228
41. C. Werner, C.H. Kamani, C. Gensch, M. Bohm, and U. Laufs The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance Diabetes 56 2007 2609 2615
42. A. Grey, V. Beckley, A. Doyle, S. Fenwick, A. Horne, and G. Gamble Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial Eur J Endocrinol 166 2012 1087 1091
43. T.A. Wren, S.A. Chung, F.J. Dorey, S. Bluml, G.B. Adams, and V. Gilsanz Bone marrow fat is inversely related to cortical bone in young and old subjects J Clin Endocrinol Metab 96 2011 782 786
44. N. Di Iorgi, S.D. Mittelman, and V. Gilsanz Differential effect of marrow adiposity and visceral and subcutaneous fat on cardiovascular risk in young, healthy adults Int J Obes (Lond) 32 2008 1854 1860
45. C.J. Rosen, C. Ackert-Bicknell, J.P. Rodriguez, and A.M. Pino Marrow fat and the bone microenvironment: developmental, functional, and pathological implications Crit Rev Eukaryot Gene Expr 19 2009 109 124
46. S. Botolin, and L.R. McCabe Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss J Cell Physiol 209 2006 967 976
47. T. Harslof, L. Wamberg, L. Moller, H. Stodkilde-Jorgensen, S. Ringgaard, and S.B. Pedersen Rosiglitazone decreases bone mass and bone marrow fat J Clin Endocrinol Metab 96 2011 1541 1548
48. J. Justesen, L. Mosekilde, M. Holmes, K. Stenderup, J. Gasser, and J.J. Mullins Mice deficient in 11beta-hydroxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation Endocrinology 145 2004 1916 1925
49. C.J. Rosen, and M.L. Bouxsein Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2 2006 35 43
50. I. Takada, A.P. Kouzmenko, and S. Kato Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis Nat Rev Rheumatol 5 2009 442 447
51. B.M. Abdallah, and M. Kassem New factors controlling the balance between osteoblastogenesis and adipogenesis Bone 50 2012 540 545
52. M. Kawai, M.J. Devlin, and C.J. Rosen Fat targets for skeletal health Nat Rev Rheumatol 5 2009 365 372
53. W. Wei, P.A. Dutchak, X. Wang, X. Ding, X. Wang, and A.L. Bookout Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma Proc Natl Acad Sci U S A 109 2012 3143 3148